市場調査レポート
商品コード
1309724

T細胞療法の世界市場規模、シェア、産業動向分析レポート:エンドユーザー別、適応症別、治療タイプ別、地域別展望と予測、2023年~2030年

Global T-Cell therapy Market Size, Share & Industry Trends Analysis Report By End User, By Indication, By Therapy Type, By Regional Outlook and Forecast, 2023 - 2030

出版日: | 発行: KBV Research | ページ情報: 英文 263 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.45円
T細胞療法の世界市場規模、シェア、産業動向分析レポート:エンドユーザー別、適応症別、治療タイプ別、地域別展望と予測、2023年~2030年
出版日: 2023年06月30日
発行: KBV Research
ページ情報: 英文 263 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

T細胞療法市場規模は2030年までに92億米ドルに達すると予測され、予測期間中のCAGRは17.5%で上昇する見込みです。

KBVカーディナルマトリックスに掲載された分析によると、ファイザー社が同市場におけるトップランナーです。2022年1月、ファイザーはドレン・バイオと研究提携およびライセンス契約を締結し、ドレン・バイオ独自の標的化骨髄エンゲイジャーと貪食プラットフォームを活用し、特定の腫瘍標的に対する治療用二重特異性抗体の探索および開発に集中します。Johnson & Johnson、AbbVie, Inc.、Novartis AGなどは、この市場における主要なイノベーターです。

市場成長要因

国際的な政府支援を得るイニシアチブの増加

血液悪性腫瘍の治療に対する政府および非営利団体の取り組みの増加は、市場機会を拡大すると予測されます。例えば、多発性骨髄腫研究財団(MMRF)とラザレックスがん財団(Lazarex Cancer Foundation)の2つの非営利団体は、2023年2月にがん臨床試験を患者にとってより利用しやすいものにするために資源を提供することを約束しました。同様に、リンパ腫研究財団(LRF)は、最先端の研究と、この病気を終わらせるための新規で効果的なリンパ腫治療法の創出を支援しています。その結果、政府支援の高まりがT細胞療法の需要を押し上げ、市場の成長を促進すると予想されます。

T細胞療法の研究開発の増加

現在も数多くの臨床試験が実施されており、CAR T細胞研究は急速に進展しています。研究者らがCAR T細胞の標的になりうる新規腫瘍細胞抗原を発見したことが、この増加の一因となっています。FDAがCAR T細胞療法として承認している抗原はCD19とBCMAの2つだけであるが、複数の抗原を同時に標的とする治療法を含め、血液悪性腫瘍で頻繁に見られるその他の抗原を標的とする新たなCAR T細胞治療法が生み出されています。ほとんどのがん患者に存在する固形がんへのCAR-Tの適用は、この分野の転換点となると思われます。したがって、ほとんどのがん症例に有効なT細胞療法を開発するための研究開発の活発化が、市場の拡大に寄与しています。

市場抑制要因

高コストと厳しい規制に関する問題

特にT細胞療法にかかるコストの高さが、この治療法の市場拡大を妨げています。他の血液がんと同様に多発性骨髄腫もあらゆる場所で増加傾向にあり、特にアジアのような発展途上国で流行しているにもかかわらず、これらの革新的な治療法の一般的な使用を妨げている障壁がいくつかあります。そのひとつが、一部の医薬品が高価なため、貧しい国々での治療率が低いことです。これらの治療法が注目されているにもかかわらず、治療を受けた人の半数以下しか長期生存していないです。これらの要素は、広く普及するための課題となっており、患者のアクセスを制限しています。

治療タイプの展望

治療法の種類によって、市場はCAR T細胞療法とT細胞受容体(TCR)ベースに分類されます。CAR T細胞療法セグメントは、2022年の市場で最も高い売上シェアを獲得しました。CAR-T療法を用いた臨床研究の増加と市場トップ企業の関与の増加が、このセグメントの上昇の原因となっています。多くの新規企業や学術機関が、さまざまな適応症に対するCAR-T療法ソリューションの臨床試験を実施しています。CAR-T療法の製造方法の改善により、さまざまな悪性腫瘍の治療におけるCAR-T療法の利用が増加しています。

CAR-T細胞療法の展望

CAR T細胞療法セグメントはさらに、アキシカブタジーンシロロイセル、チサゲンレクロロイセル、ブレクスカブタジーンオートロイセル、その他に分類されます。アキシカブタジェン・シロロイセルセグメントは、2022年のT細胞療法市場で最大の収益シェアを獲得しました。この薬剤は、少なくとも2種類の全身療法を受けても再発または改善しなかった濾胞性リンパ腫または特定のタイプの大細胞型B細胞リンパ腫の成人患者を治療することを目的としています。さらに、リンパ腫のようないくつかのがんの治療薬としても研究されています。非ホジキンリンパ腫(NHL)の中で2番目に多い濾胞性リンパ腫(FL)は、全リンパ腫の約30%を占める。そのため、これらの薬剤に対する需要は増加しています。

適応症の展望

適応症別に見ると、市場はリンパ腫、急性リンパ性白血病、その他に分けられます。急性リンパ性白血病分野は、2022年の市場成長率が顕著でした。従来の薬では治療が困難なことが多い疾患を治療するための養子細胞移植療法の開発が、関心を集めると予想されます。さらに、TCRをベースとしたものを含むT細胞療法技術の最近の開発により、多発性骨髄腫やメラノーマの治療において有望な結果が示されています。

エンドユーザーの展望

エンドユーザーに基づき、市場は病院とがん治療センターに区分されます。病院セグメントは、2022年の市場で最も高い売上シェアを獲得しました。T細胞治療に必要な確立されたインフラと最先端の医療設備により、病院セグメントは成長しています。さらに、入院患者数の増加、多発性骨髄腫の症例数の増加、より良い患者サービスを可能にする熟練した医療従事者がこれらの施設に存在することなどが、患者の間で病院への選好を高めています。

地域別展望

地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。北米セグメントは、2022年の市場において最大の収益シェアを記録しました。この地域の市場成長は、がん患者の増加、民間および政府機関の資金提供の増加、研究と商業化のための強固な基盤に関連しています。さらに、北米では高齢者の増加によりがんの有病率が上昇しており、最適な治療法の必要性が高まっています。

目次

第1章 市場範囲と調査手法

  • 市場の定義
  • 目的
  • 市場範囲
  • セグメンテーション
  • 調査手法

第2章 市場概要

  • イントロダクション
    • 概要
      • 市場構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場抑制要因

第3章 競合分析- 世界

  • KBVカーディナルマトリックス
  • 最近の業界全体の戦略的展開
    • 提携、協定、および契約
    • 製品の発売と製品の拡大
    • 買収と合併
    • 地理的拡大
    • 試験と承認
  • 主要成功戦略
    • 主な戦略
    • 主要な戦略的動き

第4章 世界のT細胞療法市場:エンドユーザー別

  • 世界の病院市場:地域別
  • 世界のがん治療センター市場:地域別

第5章 世界のT細胞療法市場:適応症別

  • 世界のリンパ腫市場:地域別
  • 世界の急性リンパ性白血病市場:地域別
  • 世界のその他の市場:地域別

第6章 世界のT細胞療法市場:治療タイプ別

  • 世界のCAR-T細胞療法市場:地域別
  • 世界のT細胞療法市場:CAR-T細胞療法の種類別
    • 世界のアキシカブタゲンシロロイセル市場:地域別
    • 世界のティサゲンルクルーセル市場:地域別
    • 世界のブレクスカブタジェン・オートルーセル市場:地域別
    • 世界のその他の市場:地域別
  • 世界のT細胞受容体(TCR)ベースの市場:地域別

第7章 世界のT細胞療法市場:地域別

  • 北米
    • 北米の市場:国別
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州の市場:国別
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州地域
  • アジア太平洋
    • アジア太平洋の市場:国別
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ラテンアメリカ・中東・アフリカの市場:国別
      • ブラジル
      • アルゼンチン
      • アラブ首長国連邦
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他ラテンアメリカ・中東・アフリカ地域

第8章 企業プロファイル

  • Merck KGaA
  • Johnson & Johnson
  • AbbVie, Inc
  • Gilead Sciences, Inc
  • Amgen, Inc
  • Novartis AG
  • Sorrento Therapeutics, Inc
  • Bristol Myers Squibb Company
  • Pfizer, Inc
  • Immunocore Holdings plc
図表

LIST OF TABLES

  • TABLE 1 Global T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 2 Global T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- T-Cell therapy Market
  • TABLE 4 Product Launches And Product Expansions- T-Cell therapy Market
  • TABLE 5 Acquisition and Mergers- T-Cell therapy Market
  • TABLE 6 Geographical Expansions - T-Cell therapy Market
  • TABLE 7 Trials and Approvals - T-Cell therapy Market
  • TABLE 8 Global T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 9 Global T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 10 Global Hospitals Market by Region, 2019 - 2022, USD Million
  • TABLE 11 Global Hospitals Market by Region, 2023 - 2030, USD Million
  • TABLE 12 Global Cancer Treatment Centers Market by Region, 2019 - 2022, USD Million
  • TABLE 13 Global Cancer Treatment Centers Market by Region, 2023 - 2030, USD Million
  • TABLE 14 Global T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 15 Global T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 16 Global Lymphoma Market by Region, 2019 - 2022, USD Million
  • TABLE 17 Global Lymphoma Market by Region, 2023 - 2030, USD Million
  • TABLE 18 Global Acute Lymphocytic Leukemia Market by Region, 2019 - 2022, USD Million
  • TABLE 19 Global Acute Lymphocytic Leukemia Market by Region, 2023 - 2030, USD Million
  • TABLE 20 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 21 Global Others Market by Region, 2023 - 2030, USD Million
  • TABLE 22 Global T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 23 Global T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 24 Global CAR T-Cell Therapy Market by Region, 2019 - 2022, USD Million
  • TABLE 25 Global CAR T-Cell Therapy Market by Region, 2023 - 2030, USD Million
  • TABLE 26 Global T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 27 Global T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 28 Global Axicabtagene Ciloleucel Market by Region, 2019 - 2022, USD Million
  • TABLE 29 Global Axicabtagene Ciloleucel Market by Region, 2023 - 2030, USD Million
  • TABLE 30 Global Tisagenlecleucel Market by Region, 2019 - 2022, USD Million
  • TABLE 31 Global Tisagenlecleucel Market by Region, 2023 - 2030, USD Million
  • TABLE 32 Global Brexucabtagene Autoleucel Market by Region, 2019 - 2022, USD Million
  • TABLE 33 Global Brexucabtagene Autoleucel Market by Region, 2023 - 2030, USD Million
  • TABLE 34 Global Others Market by Region, 2019 - 2022, USD Million
  • TABLE 35 Global Others Market by Region, 2023 - 2030, USD Million
  • TABLE 36 Global T-Cell Receptor (TCR)-Based Market by Region, 2019 - 2022, USD Million
  • TABLE 37 Global T-Cell Receptor (TCR)-Based Market by Region, 2023 - 2030, USD Million
  • TABLE 38 Global T-Cell therapy Market by Region, 2019 - 2022, USD Million
  • TABLE 39 Global T-Cell therapy Market by Region, 2023 - 2030, USD Million
  • TABLE 40 North America T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 41 North America T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 42 North America T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 43 North America T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 44 North America Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 45 North America Hospitals Market by Country, 2023 - 2030, USD Million
  • TABLE 46 North America Cancer Treatment Centers Market by Country, 2019 - 2022, USD Million
  • TABLE 47 North America Cancer Treatment Centers Market by Country, 2023 - 2030, USD Million
  • TABLE 48 North America T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 49 North America T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 50 North America Lymphoma Market by Country, 2019 - 2022, USD Million
  • TABLE 51 North America Lymphoma Market by Country, 2023 - 2030, USD Million
  • TABLE 52 North America Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
  • TABLE 53 North America Acute Lymphocytic Leukemia Market by Country, 2023 - 2030, USD Million
  • TABLE 54 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 55 North America Others Market by Country, 2023 - 2030, USD Million
  • TABLE 56 North America T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 57 North America T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 58 North America CAR T-Cell Therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 59 North America CAR T-Cell Therapy Market by Country, 2023 - 2030, USD Million
  • TABLE 60 North America T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 61 North America T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 62 North America Axicabtagene Ciloleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 63 North America Axicabtagene Ciloleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 64 North America Tisagenlecleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 65 North America Tisagenlecleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 66 North America Brexucabtagene Autoleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 67 North America Brexucabtagene Autoleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 68 North America Others Market by Country, 2019 - 2022, USD Million
  • TABLE 69 North America Others Market by Country, 2023 - 2030, USD Million
  • TABLE 70 North America T-Cell Receptor (TCR)-Based Market by Country, 2019 - 2022, USD Million
  • TABLE 71 North America T-Cell Receptor (TCR)-Based Market by Country, 2023 - 2030, USD Million
  • TABLE 72 North America T-Cell therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 73 North America T-Cell therapy Market by Country, 2023 - 2030, USD Million
  • TABLE 74 US T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 75 US T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 76 US T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 77 US T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 78 US T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 79 US T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 80 US T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 81 US T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 82 US T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 83 US T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 84 Canada T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 85 Canada T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 86 Canada T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 87 Canada T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 88 Canada T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 89 Canada T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 90 Canada T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 91 Canada T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 92 Canada T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 93 Canada T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 94 Mexico T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 95 Mexico T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 96 Mexico T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 97 Mexico T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 98 Mexico T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 99 Mexico T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 100 Mexico T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 101 Mexico T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 102 Mexico T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 103 Mexico T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 104 Rest of North America T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 105 Rest of North America T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 106 Rest of North America T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 107 Rest of North America T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 108 Rest of North America T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 109 Rest of North America T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 110 Rest of North America T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 111 Rest of North America T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 112 Rest of North America T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 113 Rest of North America T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 114 Europe T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 115 Europe T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 116 Europe T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 117 Europe T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 118 Europe Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 119 Europe Hospitals Market by Country, 2023 - 2030, USD Million
  • TABLE 120 Europe Cancer Treatment Centers Market by Country, 2019 - 2022, USD Million
  • TABLE 121 Europe Cancer Treatment Centers Market by Country, 2023 - 2030, USD Million
  • TABLE 122 Europe T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 123 Europe T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 124 Europe Lymphoma Market by Country, 2019 - 2022, USD Million
  • TABLE 125 Europe Lymphoma Market by Country, 2023 - 2030, USD Million
  • TABLE 126 Europe Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
  • TABLE 127 Europe Acute Lymphocytic Leukemia Market by Country, 2023 - 2030, USD Million
  • TABLE 128 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 129 Europe Others Market by Country, 2023 - 2030, USD Million
  • TABLE 130 Europe T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 131 Europe T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 132 Europe CAR T-Cell Therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 133 Europe CAR T-Cell Therapy Market by Country, 2023 - 2030, USD Million
  • TABLE 134 Europe T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 135 Europe T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 136 Europe Axicabtagene Ciloleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 137 Europe Axicabtagene Ciloleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 138 Europe Tisagenlecleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 139 Europe Tisagenlecleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 140 Europe Brexucabtagene Autoleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 141 Europe Brexucabtagene Autoleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 142 Europe Others Market by Country, 2019 - 2022, USD Million
  • TABLE 143 Europe Others Market by Country, 2023 - 2030, USD Million
  • TABLE 144 Europe T-Cell Receptor (TCR)-Based Market by Country, 2019 - 2022, USD Million
  • TABLE 145 Europe T-Cell Receptor (TCR)-Based Market by Country, 2023 - 2030, USD Million
  • TABLE 146 Europe T-Cell therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 147 Europe T-Cell therapy Market by Country, 2023 - 2030, USD Million
  • TABLE 148 Germany T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 149 Germany T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 150 Germany T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 151 Germany T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 152 Germany T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 153 Germany T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 154 Germany T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 155 Germany T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 156 Germany T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 157 Germany T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 158 UK T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 159 UK T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 160 UK T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 161 UK T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 162 UK T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 163 UK T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 164 UK T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 165 UK T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 166 UK T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 167 UK T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 168 France T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 169 France T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 170 France T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 171 France T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 172 France T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 173 France T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 174 France T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 175 France T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 176 France T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 177 France T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 178 Russia T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 179 Russia T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 180 Russia T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 181 Russia T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 182 Russia T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 183 Russia T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 184 Russia T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 185 Russia T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 186 Russia T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 187 Russia T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 188 Spain T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 189 Spain T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 190 Spain T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 191 Spain T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 192 Spain T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 193 Spain T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 194 Spain T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 195 Spain T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 196 Spain T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 197 Spain T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 198 Italy T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 199 Italy T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 200 Italy T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 201 Italy T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 202 Italy T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 203 Italy T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 204 Italy T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 205 Italy T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 206 Italy T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 207 Italy T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 208 Rest of Europe T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 209 Rest of Europe T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 210 Rest of Europe T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 211 Rest of Europe T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 212 Rest of Europe T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 213 Rest of Europe T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 214 Rest of Europe T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 215 Rest of Europe T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 216 Rest of Europe T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 217 Rest of Europe T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 218 Asia Pacific T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 219 Asia Pacific T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 220 Asia Pacific T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 221 Asia Pacific T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 222 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 223 Asia Pacific Hospitals Market by Country, 2023 - 2030, USD Million
  • TABLE 224 Asia Pacific Cancer Treatment Centers Market by Country, 2019 - 2022, USD Million
  • TABLE 225 Asia Pacific Cancer Treatment Centers Market by Country, 2023 - 2030, USD Million
  • TABLE 226 Asia Pacific T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 227 Asia Pacific T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 228 Asia Pacific Lymphoma Market by Country, 2019 - 2022, USD Million
  • TABLE 229 Asia Pacific Lymphoma Market by Country, 2023 - 2030, USD Million
  • TABLE 230 Asia Pacific Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
  • TABLE 231 Asia Pacific Acute Lymphocytic Leukemia Market by Country, 2023 - 2030, USD Million
  • TABLE 232 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 233 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
  • TABLE 234 Asia Pacific T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 235 Asia Pacific T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 236 Asia Pacific CAR T-Cell Therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 237 Asia Pacific CAR T-Cell Therapy Market by Country, 2023 - 2030, USD Million
  • TABLE 238 Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 239 Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 240 Asia Pacific Axicabtagene Ciloleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 241 Asia Pacific Axicabtagene Ciloleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 242 Asia Pacific Tisagenlecleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 243 Asia Pacific Tisagenlecleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 244 Asia Pacific Brexucabtagene Autoleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 245 Asia Pacific Brexucabtagene Autoleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 246 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
  • TABLE 247 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
  • TABLE 248 Asia Pacific T-Cell Receptor (TCR)-Based Market by Country, 2019 - 2022, USD Million
  • TABLE 249 Asia Pacific T-Cell Receptor (TCR)-Based Market by Country, 2023 - 2030, USD Million
  • TABLE 250 Asia Pacific T-Cell therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 251 Asia Pacific T-Cell therapy Market by Country, 2023 - 2030, USD Million
  • TABLE 252 China T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 253 China T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 254 China T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 255 China T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 256 China T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 257 China T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 258 China T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 259 China T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 260 China T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 261 China T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 262 Japan T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 263 Japan T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 264 Japan T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 265 Japan T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 266 Japan T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 267 Japan T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 268 Japan T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 269 Japan T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 270 Japan T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 271 Japan T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 272 India T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 273 India T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 274 India T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 275 India T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 276 India T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 277 India T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 278 India T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 279 India T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 280 India T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 281 India T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 282 South Korea T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 283 South Korea T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 284 South Korea T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 285 South Korea T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 286 South Korea T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 287 South Korea T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 288 South Korea T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 289 South Korea T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 290 South Korea T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 291 South Korea T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 292 Singapore T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 293 Singapore T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 294 Singapore T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 295 Singapore T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 296 Singapore T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 297 Singapore T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 298 Singapore T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 299 Singapore T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 300 Singapore T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 301 Singapore T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 302 Malaysia T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 303 Malaysia T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 304 Malaysia T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 305 Malaysia T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 306 Malaysia T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 307 Malaysia T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 308 Malaysia T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 309 Malaysia T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 310 Malaysia T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 311 Malaysia T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 312 Rest of Asia Pacific T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 313 Rest of Asia Pacific T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 314 Rest of Asia Pacific T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 315 Rest of Asia Pacific T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 316 Rest of Asia Pacific T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 317 Rest of Asia Pacific T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 318 Rest of Asia Pacific T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 319 Rest of Asia Pacific T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 320 Rest of Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 321 Rest of Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 322 LAMEA T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 323 LAMEA T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 324 LAMEA T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 325 LAMEA T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 326 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
  • TABLE 327 LAMEA Hospitals Market by Country, 2023 - 2030, USD Million
  • TABLE 328 LAMEA Cancer Treatment Centers Market by Country, 2019 - 2022, USD Million
  • TABLE 329 LAMEA Cancer Treatment Centers Market by Country, 2023 - 2030, USD Million
  • TABLE 330 LAMEA T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 331 LAMEA T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 332 LAMEA Lymphoma Market by Country, 2019 - 2022, USD Million
  • TABLE 333 LAMEA Lymphoma Market by Country, 2023 - 2030, USD Million
  • TABLE 334 LAMEA Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
  • TABLE 335 LAMEA Acute Lymphocytic Leukemia Market by Country, 2023 - 2030, USD Million
  • TABLE 336 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 337 LAMEA Others Market by Country, 2023 - 2030, USD Million
  • TABLE 338 LAMEA T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 339 LAMEA T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 340 LAMEA CAR T-Cell Therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 341 LAMEA CAR T-Cell Therapy Market by Country, 2023 - 2030, USD Million
  • TABLE 342 LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 343 LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 344 LAMEA Axicabtagene Ciloleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 345 LAMEA Axicabtagene Ciloleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 346 LAMEA Tisagenlecleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 347 LAMEA Tisagenlecleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 348 LAMEA Brexucabtagene Autoleucel Market by Country, 2019 - 2022, USD Million
  • TABLE 349 LAMEA Brexucabtagene Autoleucel Market by Country, 2023 - 2030, USD Million
  • TABLE 350 LAMEA Others Market by Country, 2019 - 2022, USD Million
  • TABLE 351 LAMEA Others Market by Country, 2023 - 2030, USD Million
  • TABLE 352 LAMEA T-Cell Receptor (TCR)-Based Market by Country, 2019 - 2022, USD Million
  • TABLE 353 LAMEA T-Cell Receptor (TCR)-Based Market by Country, 2023 - 2030, USD Million
  • TABLE 354 LAMEA T-Cell therapy Market by Country, 2019 - 2022, USD Million
  • TABLE 355 LAMEA T-Cell therapy Market by Country, 2023 - 2030, USD Million
  • TABLE 356 Brazil T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 357 Brazil T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 358 Brazil T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 359 Brazil T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 360 Brazil T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 361 Brazil T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 362 Brazil T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 363 Brazil T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 364 Brazil T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 365 Brazil T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 366 Argentina T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 367 Argentina T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 368 Argentina T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 369 Argentina T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 370 Argentina T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 371 Argentina T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 372 Argentina T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 373 Argentina T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 374 Argentina T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 375 Argentina T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 376 UAE T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 377 UAE T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 378 UAE T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 379 UAE T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 380 UAE T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 381 UAE T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 382 UAE T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 383 UAE T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 384 UAE T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 385 UAE T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 386 Saudi Arabia T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 387 Saudi Arabia T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 388 Saudi Arabia T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 389 Saudi Arabia T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 390 Saudi Arabia T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 391 Saudi Arabia T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 392 Saudi Arabia T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 393 Saudi Arabia T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 394 Saudi Arabia T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 395 Saudi Arabia T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 396 South Africa T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 397 South Africa T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 398 South Africa T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 399 South Africa T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 400 South Africa T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 401 South Africa T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 402 South Africa T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 403 South Africa T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 404 South Africa T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 405 South Africa T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 406 Nigeria T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 407 Nigeria T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 408 Nigeria T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 409 Nigeria T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 410 Nigeria T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 411 Nigeria T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 412 Nigeria T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 413 Nigeria T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 414 Nigeria T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 415 Nigeria T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 416 Rest of LAMEA T-Cell therapy Market, 2019 - 2022, USD Million
  • TABLE 417 Rest of LAMEA T-Cell therapy Market, 2023 - 2030, USD Million
  • TABLE 418 Rest of LAMEA T-Cell therapy Market by End User, 2019 - 2022, USD Million
  • TABLE 419 Rest of LAMEA T-Cell therapy Market by End User, 2023 - 2030, USD Million
  • TABLE 420 Rest of LAMEA T-Cell therapy Market by Indication, 2019 - 2022, USD Million
  • TABLE 421 Rest of LAMEA T-Cell therapy Market by Indication, 2023 - 2030, USD Million
  • TABLE 422 Rest of LAMEA T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
  • TABLE 423 Rest of LAMEA T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
  • TABLE 424 Rest of LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
  • TABLE 425 Rest of LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
  • TABLE 426 key Information - Merck KGaA
  • TABLE 427 Key information -Johnson & Johnson
  • TABLE 428 Key information - AbbVie, Inc.
  • TABLE 429 Key Information - Gilead Sciences, Inc.
  • TABLE 430 Key Information - Amgen, Inc.
  • TABLE 431 Key Information - Novartis AG
  • TABLE 432 Key Information - Sorrento Therapeutics, Inc.
  • TABLE 433 Key Information - Bristol Myers Squibb Company
  • TABLE 434 Key Information - Pfizer, Inc.
  • TABLE 435 Key Information - Immunocore Holdings plc

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
  • FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep - 2023, May) Leading Players
  • FIG 5 Global T-Cell therapy Market share by End User, 2022
  • FIG 6 Global T-Cell therapy Market share by End User, 2030
  • FIG 7 Global T-Cell therapy Market by End User, 2019 - 2030, USD Million
  • FIG 8 Global T-Cell therapy Market share by Indication, 2022
  • FIG 9 Global T-Cell therapy Market share by Indication, 2030
  • FIG 10 Global T-Cell therapy Market by Indication, 2019 - 2030, USD Million
  • FIG 11 Global T-Cell therapy Market share by Therapy Type, 2022
  • FIG 12 Global T-Cell therapy Market share by Therapy Type, 2030
  • FIG 13 Global T-Cell therapy Market by Therapy Type, 2019 - 2030, USD Million
  • FIG 14 Global T-Cell therapy Market share by Region, 2022
  • FIG 15 Global T-Cell therapy Market share by Region, 2030
  • FIG 16 Global T-Cell therapy Market by Region, 2019 - 2030, USD Million
  • FIG 17 Recent strategies and developments: Merck KGaA
  • FIG 18 Recent strategies and developments: Johnson & Johnson
  • FIG 19 SWOT analysis: Johnson & Johnson
  • FIG 20 Recent strategies and developments: Gilead Sciences, Inc.
  • FIG 21 Recent strategies and developments: Amgen, Inc.
  • FIG 22 Recent strategies and developments: Novartis AG
  • FIG 23 Recent strategies and developments: Sorrento Therapeutics, Inc.
  • FIG 24 Recent strategies and developments: Bristol Myers Squibb Company
  • FIG 25 Recent strategies and developments: Pfizer, Inc.
  • FIG 26 Recent strategies and developments: Immunocore Holdings plc
目次

The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period.

Acute Lymphocytic Leukemia is the growing indication type of T-Cell Therapy because of the increasing prevalence of multiple myeloma and the increased research & development. Therefore, acute lymphocytic leukemia is anticipated to generate more than 35% share of the market by 2030. For example, according to the National Center for Biotechnology Information (NCBI), presently, there are 160,000 new cases of MM per year, with 106,000 deaths. 10% of all diagnosed hematological cancers are multiple myeloma, which has gained clinical attention due to major improvements in medical care.

For instance, according to Cancer Australia, there are expected to be 2,625 additional instances of multiple myeloma diagnosed in Australia in 2022. The same source estimates that at 85, a person will have a 1 in 111 chance of receiving a diagnosis with multiple myeloma. The expansion of T-cell therapies is also being aided by the rising number of approvals. For instance, the FDA expedited the approval of teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific BCMA-directed CD3 T-cell engager, in October 2022 for adults with relapsed or refractory (r/r) multiple myeloma.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In May, 2023, Amgen entered into collaboration with TScan Therapeutics, Inc. to leverage TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease and enable the company to develop first-in-class therapeutics to address unmet medical needs. Additionally, In May, 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, teamed up with Cellular Biomedicine Group Inc. to enhance its portfolio in B-cell malignancies and accelerate the development, manufacturing, and commercialization capabilities to deliver best-in-class cell therapies.

Based on the Analysis presented in the KBV Cardinal matrix; Pfizer, Inc. is the forerunner in the Market. In January, 2022, Pfizer signed a research collaboration and license agreement with Dren Bio to concentrate on the discovery and development of therapeutic bispecific antibodies for select oncology targets utilizing Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform. Companies such as Johnson & Johnson, AbbVie, Inc., Novartis AG are some of the key innovators in the Market.

Market Growth Factors

Rising number of initiatives gaining more international government support

Increased government as well as nonprofit organization efforts to treat hematological malignancies are predicted to improve the market opportunity. For instance, two nonprofit organizations, the Multiple Myeloma Research Foundation (MMRF) and the Lazarex Cancer Foundation, committed their resources to make cancer clinical trials more accessible to patients in February 2023. Similarly, the Lymphoma Research Foundation (LRF) supports cutting-edge research and the creation of novel, effective lymphoma therapies to end this illness. As a result, rising government support is anticipated to boost demand for T-cell therapies and propel market growth.

Growing number of research and development in T-cell therapies

Numerous clinical trials are still being conducted, and CAR T-cell research is progressing quickly. Researchers' discovery of novel tumor cell antigens that potentially make suitable CAR T- cell targets has contributed to some of this increase. Although the only two antigens that have FDA approval for CAR T-cell therapies are CD19 and BCMA, new CAR T-cell treatments have been created that target additional antigens frequently seen in blood malignancies, including treatments that target multiple antigens simultaneously. The application of CAR T to solid tumors, which are present in most cancer patients, will mark a turning point in the field. Hence, the increasing R&D in developing T-cell therapies effective in most cancer cases is aiding in expanding the market.

Market Restraining Factors

Issues related to high cost and strict regulations

Numerous problems, notably the high cost of T-cell therapy, are impeding the market expansion of this treatment. Even though multiple myelomas, as well as other blood cancers, are on the rise everywhere and are particularly prevalent in developing nations like Asia, there are several barriers hindering the general use of these innovative treatments. One of these is the low treatment rates in poor countries due to the expensive costs of some medicines. Despite all the attention surrounding these treatments, less than half of those who receive them survive for a long time. These elements present a challenge to its wide adoption and restrict patient access.

Therapy Type Outlook

Based on therapy type, the market is characterized into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment garnered the highest revenue share in the market in 2022. The increase in clinical studies using CAR-T therapy and the increasing involvement of the market's top companies is responsible for the segment's rise. Many new companies and academic institutions are conducting clinical trials for CAR-T therapy solutions for various indications. Improvements in its manufacture have led to an increase in the utilization of CAR-T procedures in the treatment of various malignancies.

Car T-Cell Therapy Outlook

The CAR T-cell therapy segment is further classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. The axicabtagene ciloleucel segment acquired the largest revenue share in the T-cell therapy market in 2022. This medication is intended to treat adult patients with follicular lymphoma or specific types of large B-cell lymphoma who had either relapsed or failed to improve after receiving at least two different forms of systemic therapy. Additionally, it is being researched for the treatment of several cancers like lymphoma. The second most prevalent form of non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), makes up about 30% of all lymphomas. Therefore, the demand for these medications is increasing.

Indication Outlook

By indication, the market is divided into lymphoma, acute lymphocytic leukemia, and others. The acute lymphocytic leukemia segment garnered a remarkable growth rate in the market in 2022. The development of adoptive cell transfer therapy for treating disorders, which are frequently more challenging to treat with conventional medicines, is expected to garner increased interest. Additionally, recent developments in T-cell therapy technology, including TCR-based, have demonstrated encouraging outcomes in managing multiple myeloma and melanoma.

End User Outlook

Based on end user, the market is segmented into hospitals and cancer treatment centers. The hospitals segment procured the highest revenue share in the market in 2022. Due to its established infrastructure and cutting-edge medical facilities, which are required for T-cell treatment, the hospital segment is growing. Additionally, an increase in the number of patients admitted, a rise in the number of cases of multiple myeloma, and the presence of skilled medical personnel in these facilities, which enables better patient services, are increasing the preference for hospitals among patients.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the market in 2022. The market growth in this region is linked to an increase in cancer cases, an increase in private and governmental agency funding, and a solid foundation for research and commercialization. Additionally, the prevalence of cancer has increased in North America due to the rise in the number of elderly people, which has increased the need for optimum therapies.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.

Recent Strategies Deployed in T-Cell Therapy Market

Partnerships, Collaboration and Agreements:

May-2023: Amgen entered into collaboration with TScan Therapeutics, Inc. a clinical-stage biopharmaceutical company. With this collaboration, the company aimed to leverage TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease and enable the company to develop first-in-class therapeutics to address unmet medical needs.

May-2023: Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, teamed up with Cellular Biomedicine Group Inc., developer of proprietary immune cell therapies for the treatment of various cancers. The collaboration enables the company to enhance its portfolio in B-cell malignancies and accelerate the development, manufacturing, and commercialization capabilities to deliver best-in-class cell therapies.

Apr-2023: Johnson & Johnson and Legend Biotech signed an agreement with Novartis, a Swiss multinational pharmaceutical corporation that engages in the development, manufacture, and marketing of healthcare products. Novartyi would supply Caryvkti from its cell therapy site in Morris Plains, New Jersey which would provide J&J and Legend with the extra clinical capacity for ramping up commercial supply.

Jan-2023: AbbVie teamed up with Immunome, Inc., a clinical-stage biopharmaceutical company, for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine. The company looks forward to utilizing its Discovery Engine to enhance the existing oncology pipeline through this collaboration.

Dec-2022: Merck KGaA entered into an agreement with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology, and Innovation. With this agreement, both companies aimed to combine capabilities for offering streamlined development, manufacturing, and testing for viral vector gene therapies for Japan.

Dec-2022: Bristol Myers Squibb formed a collaboration with Century Therapeutics, an innovative biotechnology company that builds industry-leading allogeneic iPSC-derived cell therapy platforms. With this collaboration, the company aimed to develop allogeneic cell therapies to help patients with hematologic and solid tumor malignancies.

Dec-2022: Immunocore Holdings plc joined hands with Gadeta B.V., an innovative clinical-stage biopharmaceutical company. Through this collaboration, the company aimed to combine Gadeta's expertise in gamma delta TCRs with their scientific, development, and commercialization capabilities to offer new TCR therapies.

Jan-2022: Pfizer signed a research collaboration and license agreement with Dren Bio, a biopharmaceutical company, a developer of therapeutic antibodies for the treatment of cancer. This agreement aimed to concentrate on the discovery and development of therapeutic bispecific antibodies for select oncology targets utilizing Dren Bio's proprietary Targeted Myeloid Engager and Phagocytosis Platform

Oct-2021: Immunocore entered into an agreement with Medison Pharma Ltd., a global pharma company engaged in providing access to highly innovative therapies. The agreement would enable Immunocore to obtain regulatory approval and market tebentafusp (IMCgp100) in Canada, twenty markets in Central Eastern Europe, and Israel for the treatment of metastatic uveal melanoma.

Aug-2021: Kite, a Gilead Company joined hands with Appia Bio, Inc., an early-stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients. Through this collaboration, the company aimed to tackle the unique biological properties of invariant natural killer T cells to research and develop allogeneic cell therapies for cancer.

Jun-2021: Kite, a Gilead Company formed a partnership with Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf for cancer and other serious diseases. The partnership is aimed to develop novel cell therapies across a variety of cancer targets. Initially, the collaboration would focus on chimeric antigen receptor (CAR) NK targets with the company having the option to expand the collaboration to include an iPSC CAR Macrophage program.

Mar-2021: Merck KGaA signed an agreement with Gilead Sciences, Inc., an American biopharmaceutical company. The agreement is aimed to co-develop and co-commercialize treatment options for people living with HIV by combining the company's investigational nucleoside reverse transcriptase translocation inhibitor, islatravir with Gilead's investigational capsid inhibitor, lenacapavir.

Mar-2021: Pfizer signed a worldwide license agreement with Pyxis Oncology, a preclinical oncology company. This agreement aimed to develop and commercialize two antibody-drug conjugates (ADC) candidates and a license to Pfizer's ADC technology platform, also allowing expansion of the ADC portfolio and strengthening the developmental capabilities and demonstrating successful implementation of overarching corporate strategy to align in-house organic growth with strategic in-licensing and partnerships to develop the multi-asset multi-platform portfolio.

Feb-2021: AbbVie formed a collaboration with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company. Through this collaboration, the company would be able to advance its efforts to provide new hope for patients.

Product Launch and Product Expansions:

Dec-2021: Novartis unveiled T-Charge, the company's next-generation CAR-T platform that would serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. With this launch of T-Charge, the company aimed to further reimagine CAR-T cell therapy and offer an ultimate potential for a cure by giving patients a higher likelihood of durable responses.

Acquisitions and Merger:

May-2023: Gilead Sciences completed the acquisition of XinThera, a small molecule drug discovery company. The acquisition enables the company to use XinThera's portfolio of two small molecule inhibitor programmes and improve outcomes for people living with cancer and inflammatory diseases.

Dec-2022: Kite, a Gilead Company took over Tmunity Therapeutics, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements in-house cell therapy research capabilities of Kite by adding platform capabilities, pipeline assets, and licensing agreement with the University of Pennsylvania (Penn).

Aug-2022: Bristol Myers Squibb completed the acquisition of Turning Point Therapeutics, a pharmaceutical company engaged in the discovery and development of precision medicine for cancer and other diseases. The acquisition added a product line of investigational medicines designed for targeting the most common mutations related to oncogenesis, to Bristol Myers' portfolio.

Jun-2022: Novartis acquired Kedalion Therapeutics, a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, California. Through this acquisition, Novartis attained AcuStreaM technology of Kedalion Therapeutics. The acquisition aimed to increase Novartis' ophthalmics portfolio and progressed its efforts to investigate revolutionizing ophthalmic methods that would assist in addressing unmet patient needs in front-of-eye conditions.

Feb-2022: Merck completed the acquisition of Exelead, a biopharmaceutical contract development, and manufacturing business. Through this acquisition, Exelead's leading abilities, and highly experienced crew, Merck acquires a crucial landmark in evolving one of the supreme CDMO players in mRNA vaccines and therapeutics, delivering a combined CDMO across the mRNA value chain from pre-clinical to retail.

Dec-2021: Merck signed an agreement to acquire Chord Therapeutics, a Swiss-based biotech company. By this acquisition, Merck aimed at leveraging its existing capabilities to further develop an oral cladribine product tailored particularly for MS, oncologic disorders, gMG, and NMOSD.

Dec-2021: Novartis signed an agreement to acquire Gyroscope Therapeutics, a clinical-stage gene therapy company. Through this acquisition, Novartis would achieve access to the prior guide experimental gene treatment, GT005.

Nov-2021: Pfizer acquired Trillium Therapeutics, a clinical-stage immuno-oncology company that develops innovative therapies for cancer treatment. The acquisition added a biologics portfolio that enhanced the patient's innate immune system ability to detect and destroy cancer cells.

Jul-2021: Amgen took over Teneobio, a clinical-stage biotechnology company. With this acquisition, the company aimed to leverage Teneobio's antibody platform in order to complement its prevailing capabilities. Moreover, the company also aimed to gain a diverse range of building blocks that can be created into new multispecific therapeutics.

Jun-2021: Sorrento Therapeutics, Inc. took over ACEA Therapeutics Inc., developer of oncology drugs. The company, through this acquisition, aimed to expand its development and commercialization of innovative medicines that would save and improve lives globally.

Apr-2021: Amgen took over Five Prime Therapeutics, a clinical-stage biotechnology business. Through this acquisition, the company aimed to integrate Five Prime's offerings into its oncology portfolio in order to strengthen its vision for international expansion and further pipeline programs.

Geographical Expansions:

Apr-2023: Bristol Myers Squibb expanded its geographical footprints by opening a U.S.-based manufacturing facility. The new facility would enable the company to increase its capabilities to produce viral vectors for both of Bristol Myers Squibb's CAR T cell therapies.

Trials and Approvals:

Jun-2022: Bristol Myers Squibb got approval from U.S. FDA for CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma after a Prior Therapy once. This therapy is indicated for the treatment of follicular lymphoma grade 3B, primary mediastinal large B-cell lymphoma, large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), and high-grade B-cell lymphoma, among adult patients.

May-2022: US Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) by Novartis AG for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. The approval enables the company to help break the unrelenting cycle of treatment for patients with follicular lymphoma.

Jan-2022: Kite, a Gilead Company received approval from U.S. Food and Drug Administration for Yescarta. With this approval, the company would be able to offer treatment for adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

Jan-2022: Japan's Ministry of Health, Labour and Welfare has approved Bristol-Myers Squibb's Abecma (idecabtagene violence), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, to treat adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies. The approval would enable the company to address unmet medical needs for patients in Japan and help them prevail over serious diseases.

Jan-2022: Immunocore Holdings plc received approval from United States Food and Drug Administration (FDA) for KIMMTRAK (tebentafusp-tebn), for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). With this approval, the company would be able to help those with this aggressive form of cancer.

Aug-2021: Sorrento Therapeutics, Inc received approval for Sorrento's IND application from the FDA for the Phase 1 clinical testing of allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) - T Cell therapy for relapsed or refractory multiple myeloma. This approval would open the doors for numerous other DAR-T cell therapies.

Scope of the Study

Market Segments covered in the Report:

By End User

  • Hospitals
  • Cancer Treatment Centers

By Indication

  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Others

By Therapy Type

  • CAR T-Cell Therapy
    • Axicabtagene Ciloleucel
    • Tisagenlecleucel
    • Brexucabtagene Autoleucel
    • Others
  • T-Cell Receptor (TCR)-Based

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Merck KGaA
  • Johnson & Johnson
  • AbbVie, Inc.
  • Gilead Sciences, Inc.
  • Amgen, Inc.
  • Novartis AG
  • Sorrento Therapeutics, Inc.
  • Bristol Myers Squibb Company
  • Immunocore Holdings plc
  • Pfizer, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global T-Cell therapy Market, by End User
    • 1.4.2 Global T-Cell therapy Market, by Indication
    • 1.4.3 Global T-Cell therapy Market, by Therapy Type
    • 1.4.4 Global T-Cell therapy Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
    • 3.2.4 Geographical Expansions
    • 3.2.5 Trials and Approvals
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep - 2023, May) Leading Players

Chapter 4. Global T-Cell therapy Market by End User

  • 4.1 Global Hospitals Market by Region
  • 4.2 Global Cancer Treatment Centers Market by Region

Chapter 5. Global T-Cell therapy Market by Indication

  • 5.1 Global Lymphoma Market by Region
  • 5.2 Global Acute Lymphocytic Leukemia Market by Region
  • 5.3 Global Others Market by Region

Chapter 6. Global T-Cell therapy Market by Therapy Type

  • 6.1 Global CAR T-Cell Therapy Market by Region
  • 6.2 Global T-Cell therapy Market by CAR T-Cell Therapy Type
    • 6.2.1 Global Axicabtagene Ciloleucel Market by Region
    • 6.2.2 Global Tisagenlecleucel Market by Region
    • 6.2.3 Global Brexucabtagene Autoleucel Market by Region
    • 6.2.4 Global Others Market by Region
  • 6.3 Global T-Cell Receptor (TCR)-Based Market by Region

Chapter 7. Global T-Cell therapy Market by Region

  • 7.1 North America T-Cell therapy Market
    • 7.1.1 North America T-Cell therapy Market by End User
      • 7.1.1.1 North America Hospitals Market by Country
      • 7.1.1.2 North America Cancer Treatment Centers Market by Country
    • 7.1.2 North America T-Cell therapy Market by Indication
      • 7.1.2.1 North America Lymphoma Market by Country
      • 7.1.2.2 North America Acute Lymphocytic Leukemia Market by Country
      • 7.1.2.3 North America Others Market by Country
    • 7.1.3 North America T-Cell therapy Market by Therapy Type
      • 7.1.3.1 North America CAR T-Cell Therapy Market by Country
      • 7.1.3.2 North America T-Cell therapy Market by CAR T-Cell Therapy Type
        • 7.1.3.2.1 North America Axicabtagene Ciloleucel Market by Country
        • 7.1.3.2.2 North America Tisagenlecleucel Market by Country
        • 7.1.3.2.3 North America Brexucabtagene Autoleucel Market by Country
        • 7.1.3.2.4 North America Others Market by Country
      • 7.1.3.3 North America T-Cell Receptor (TCR)-Based Market by Country
    • 7.1.4 North America T-Cell therapy Market by Country
      • 7.1.4.1 US T-Cell therapy Market
        • 7.1.4.1.1 US T-Cell therapy Market by End User
        • 7.1.4.1.2 US T-Cell therapy Market by Indication
        • 7.1.4.1.3 US T-Cell therapy Market by Therapy Type
      • 7.1.4.2 Canada T-Cell therapy Market
        • 7.1.4.2.1 Canada T-Cell therapy Market by End User
        • 7.1.4.2.2 Canada T-Cell therapy Market by Indication
        • 7.1.4.2.3 Canada T-Cell therapy Market by Therapy Type
      • 7.1.4.3 Mexico T-Cell therapy Market
        • 7.1.4.3.1 Mexico T-Cell therapy Market by End User
        • 7.1.4.3.2 Mexico T-Cell therapy Market by Indication
        • 7.1.4.3.3 Mexico T-Cell therapy Market by Therapy Type
      • 7.1.4.4 Rest of North America T-Cell therapy Market
        • 7.1.4.4.1 Rest of North America T-Cell therapy Market by End User
        • 7.1.4.4.2 Rest of North America T-Cell therapy Market by Indication
        • 7.1.4.4.3 Rest of North America T-Cell therapy Market by Therapy Type
  • 7.2 Europe T-Cell therapy Market
    • 7.2.1 Europe T-Cell therapy Market by End User
      • 7.2.1.1 Europe Hospitals Market by Country
      • 7.2.1.2 Europe Cancer Treatment Centers Market by Country
    • 7.2.2 Europe T-Cell therapy Market by Indication
      • 7.2.2.1 Europe Lymphoma Market by Country
      • 7.2.2.2 Europe Acute Lymphocytic Leukemia Market by Country
      • 7.2.2.3 Europe Others Market by Country
    • 7.2.3 Europe T-Cell therapy Market by Therapy Type
      • 7.2.3.1 Europe CAR T-Cell Therapy Market by Country
      • 7.2.3.2 Europe T-Cell therapy Market by CAR T-Cell Therapy Type
        • 7.2.3.2.1 Europe Axicabtagene Ciloleucel Market by Country
        • 7.2.3.2.2 Europe Tisagenlecleucel Market by Country
        • 7.2.3.2.3 Europe Brexucabtagene Autoleucel Market by Country
        • 7.2.3.2.4 Europe Others Market by Country
      • 7.2.3.3 Europe T-Cell Receptor (TCR)-Based Market by Country
    • 7.2.4 Europe T-Cell therapy Market by Country
      • 7.2.4.1 Germany T-Cell therapy Market
        • 7.2.4.1.1 Germany T-Cell therapy Market by End User
        • 7.2.4.1.2 Germany T-Cell therapy Market by Indication
        • 7.2.4.1.3 Germany T-Cell therapy Market by Therapy Type
      • 7.2.4.2 UK T-Cell therapy Market
        • 7.2.4.2.1 UK T-Cell therapy Market by End User
        • 7.2.4.2.2 UK T-Cell therapy Market by Indication
        • 7.2.4.2.3 UK T-Cell therapy Market by Therapy Type
      • 7.2.4.3 France T-Cell therapy Market
        • 7.2.4.3.1 France T-Cell therapy Market by End User
        • 7.2.4.3.2 France T-Cell therapy Market by Indication
        • 7.2.4.3.3 France T-Cell therapy Market by Therapy Type
      • 7.2.4.4 Russia T-Cell therapy Market
        • 7.2.4.4.1 Russia T-Cell therapy Market by End User
        • 7.2.4.4.2 Russia T-Cell therapy Market by Indication
        • 7.2.4.4.3 Russia T-Cell therapy Market by Therapy Type
      • 7.2.4.5 Spain T-Cell therapy Market
        • 7.2.4.5.1 Spain T-Cell therapy Market by End User
        • 7.2.4.5.2 Spain T-Cell therapy Market by Indication
        • 7.2.4.5.3 Spain T-Cell therapy Market by Therapy Type
      • 7.2.4.6 Italy T-Cell therapy Market
        • 7.2.4.6.1 Italy T-Cell therapy Market by End User
        • 7.2.4.6.2 Italy T-Cell therapy Market by Indication
        • 7.2.4.6.3 Italy T-Cell therapy Market by Therapy Type
      • 7.2.4.7 Rest of Europe T-Cell therapy Market
        • 7.2.4.7.1 Rest of Europe T-Cell therapy Market by End User
        • 7.2.4.7.2 Rest of Europe T-Cell therapy Market by Indication
        • 7.2.4.7.3 Rest of Europe T-Cell therapy Market by Therapy Type
  • 7.3 Asia Pacific T-Cell therapy Market
    • 7.3.1 Asia Pacific T-Cell therapy Market by End User
      • 7.3.1.1 Asia Pacific Hospitals Market by Country
      • 7.3.1.2 Asia Pacific Cancer Treatment Centers Market by Country
    • 7.3.2 Asia Pacific T-Cell therapy Market by Indication
      • 7.3.2.1 Asia Pacific Lymphoma Market by Country
      • 7.3.2.2 Asia Pacific Acute Lymphocytic Leukemia Market by Country
      • 7.3.2.3 Asia Pacific Others Market by Country
    • 7.3.3 Asia Pacific T-Cell therapy Market by Therapy Type
      • 7.3.3.1 Asia Pacific CAR T-Cell Therapy Market by Country
      • 7.3.3.2 Asia Pacific T-Cell therapy Market by CAR T-Cell Therapy Type
        • 7.3.3.2.1 Asia Pacific Axicabtagene Ciloleucel Market by Country
        • 7.3.3.2.2 Asia Pacific Tisagenlecleucel Market by Country
        • 7.3.3.2.3 Asia Pacific Brexucabtagene Autoleucel Market by Country
        • 7.3.3.2.4 Asia Pacific Others Market by Country
      • 7.3.3.3 Asia Pacific T-Cell Receptor (TCR)-Based Market by Country
    • 7.3.4 Asia Pacific T-Cell therapy Market by Country
      • 7.3.4.1 China T-Cell therapy Market
        • 7.3.4.1.1 China T-Cell therapy Market by End User
        • 7.3.4.1.2 China T-Cell therapy Market by Indication
        • 7.3.4.1.3 China T-Cell therapy Market by Therapy Type
      • 7.3.4.2 Japan T-Cell therapy Market
        • 7.3.4.2.1 Japan T-Cell therapy Market by End User
        • 7.3.4.2.2 Japan T-Cell therapy Market by Indication
        • 7.3.4.2.3 Japan T-Cell therapy Market by Therapy Type
      • 7.3.4.3 India T-Cell therapy Market
        • 7.3.4.3.1 India T-Cell therapy Market by End User
        • 7.3.4.3.2 India T-Cell therapy Market by Indication
        • 7.3.4.3.3 India T-Cell therapy Market by Therapy Type
      • 7.3.4.4 South Korea T-Cell therapy Market
        • 7.3.4.4.1 South Korea T-Cell therapy Market by End User
        • 7.3.4.4.2 South Korea T-Cell therapy Market by Indication
        • 7.3.4.4.3 South Korea T-Cell therapy Market by Therapy Type
      • 7.3.4.5 Singapore T-Cell therapy Market
        • 7.3.4.5.1 Singapore T-Cell therapy Market by End User
        • 7.3.4.5.2 Singapore T-Cell therapy Market by Indication
        • 7.3.4.5.3 Singapore T-Cell therapy Market by Therapy Type
      • 7.3.4.6 Malaysia T-Cell therapy Market
        • 7.3.4.6.1 Malaysia T-Cell therapy Market by End User
        • 7.3.4.6.2 Malaysia T-Cell therapy Market by Indication
        • 7.3.4.6.3 Malaysia T-Cell therapy Market by Therapy Type
      • 7.3.4.7 Rest of Asia Pacific T-Cell therapy Market
        • 7.3.4.7.1 Rest of Asia Pacific T-Cell therapy Market by End User
        • 7.3.4.7.2 Rest of Asia Pacific T-Cell therapy Market by Indication
        • 7.3.4.7.3 Rest of Asia Pacific T-Cell therapy Market by Therapy Type
  • 7.4 LAMEA T-Cell therapy Market
    • 7.4.1 LAMEA T-Cell therapy Market by End User
      • 7.4.1.1 LAMEA Hospitals Market by Country
      • 7.4.1.2 LAMEA Cancer Treatment Centers Market by Country
    • 7.4.2 LAMEA T-Cell therapy Market by Indication
      • 7.4.2.1 LAMEA Lymphoma Market by Country
      • 7.4.2.2 LAMEA Acute Lymphocytic Leukemia Market by Country
      • 7.4.2.3 LAMEA Others Market by Country
    • 7.4.3 LAMEA T-Cell therapy Market by Therapy Type
      • 7.4.3.1 LAMEA CAR T-Cell Therapy Market by Country
      • 7.4.3.2 LAMEA T-Cell therapy Market by CAR T-Cell Therapy Type
        • 7.4.3.2.1 LAMEA Axicabtagene Ciloleucel Market by Country
        • 7.4.3.2.2 LAMEA Tisagenlecleucel Market by Country
        • 7.4.3.2.3 LAMEA Brexucabtagene Autoleucel Market by Country
        • 7.4.3.2.4 LAMEA Others Market by Country
      • 7.4.3.3 LAMEA T-Cell Receptor (TCR)-Based Market by Country
    • 7.4.4 LAMEA T-Cell therapy Market by Country
      • 7.4.4.1 Brazil T-Cell therapy Market
        • 7.4.4.1.1 Brazil T-Cell therapy Market by End User
        • 7.4.4.1.2 Brazil T-Cell therapy Market by Indication
        • 7.4.4.1.3 Brazil T-Cell therapy Market by Therapy Type
      • 7.4.4.2 Argentina T-Cell therapy Market
        • 7.4.4.2.1 Argentina T-Cell therapy Market by End User
        • 7.4.4.2.2 Argentina T-Cell therapy Market by Indication
        • 7.4.4.2.3 Argentina T-Cell therapy Market by Therapy Type
      • 7.4.4.3 UAE T-Cell therapy Market
        • 7.4.4.3.1 UAE T-Cell therapy Market by End User
        • 7.4.4.3.2 UAE T-Cell therapy Market by Indication
        • 7.4.4.3.3 UAE T-Cell therapy Market by Therapy Type
      • 7.4.4.4 Saudi Arabia T-Cell therapy Market
        • 7.4.4.4.1 Saudi Arabia T-Cell therapy Market by End User
        • 7.4.4.4.2 Saudi Arabia T-Cell therapy Market by Indication
        • 7.4.4.4.3 Saudi Arabia T-Cell therapy Market by Therapy Type
      • 7.4.4.5 South Africa T-Cell therapy Market
        • 7.4.4.5.1 South Africa T-Cell therapy Market by End User
        • 7.4.4.5.2 South Africa T-Cell therapy Market by Indication
        • 7.4.4.5.3 South Africa T-Cell therapy Market by Therapy Type
      • 7.4.4.6 Nigeria T-Cell therapy Market
        • 7.4.4.6.1 Nigeria T-Cell therapy Market by End User
        • 7.4.4.6.2 Nigeria T-Cell therapy Market by Indication
        • 7.4.4.6.3 Nigeria T-Cell therapy Market by Therapy Type
      • 7.4.4.7 Rest of LAMEA T-Cell therapy Market
        • 7.4.4.7.1 Rest of LAMEA T-Cell therapy Market by End User
        • 7.4.4.7.2 Rest of LAMEA T-Cell therapy Market by Indication
        • 7.4.4.7.3 Rest of LAMEA T-Cell therapy Market by Therapy Type

Chapter 8. Company Profiles

  • 8.1 Merck KGaA
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental and Regional Analysis
    • 8.1.4 Research & Development Expense
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Partnerships, Collaborations, and Agreements:
      • 8.1.5.2 Acquisition and Mergers:
  • 8.2 Johnson & Johnson
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Segmental &Regional Analysis
    • 8.2.4 Research & Development Expenses
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Partnerships, Collaborations, and Agreements:
      • 8.2.5.2 Acquisition and Mergers:
  • 8.3 AbbVie, Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Regional Analysis
    • 8.3.4 Research & Development Expense
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Partnerships, Collaborations, and Agreements:
  • 8.4 Gilead Sciences, Inc.
    • 8.4.1 Company overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Research & Development Expenses
    • 8.4.4 Recent strategies and developments:
      • 8.4.4.1 Partnerships, Collaborations, and Agreements:
      • 8.4.4.2 Acquisition and Mergers:
      • 8.4.4.3 Trials and Approvals:
  • 8.5 Amgen, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Regional Analysis
    • 8.5.4 Research & Development Expenses
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Partnerships, Collaborations, and Agreements:
      • 8.5.5.2 Acquisition and Mergers:
  • 8.6 Novartis AG
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Segmental and Regional Analysis
    • 8.6.4 Research & Development Expense
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Product Launches and Product Expansions:
      • 8.6.5.2 Acquisition and Mergers:
      • 8.6.5.3 Trials and Approvals:
  • 8.7 Sorrento Therapeutics, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Segmental Analysis
    • 8.7.4 Research & Development Expenses
    • 8.7.5 Recent strategies and developments:
      • 8.7.5.1 Acquisition and Mergers:
      • 8.7.5.2 Trials and Approvals:
  • 8.8 Bristol Myers Squibb Company
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Regional Analysis
    • 8.8.4 Research & Development Expenses
    • 8.8.5 Recent strategies and developments:
      • 8.8.5.1 Partnerships, Collaborations, and Agreements:
      • 8.8.5.2 Acquisition and Mergers:
      • 8.8.5.3 Geographical Expansions:
      • 8.8.5.4 Trials and Approvals:
  • 8.9 Pfizer, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional & Segmental Analysis
    • 8.9.4 Research & Development Expense
    • 8.9.5 Recent strategies and developments:
      • 8.9.5.1 Partnerships, Collaborations, and Agreements:
      • 8.9.5.2 Acquisition and Mergers:
  • 8.10. Immunocore Holdings plc
    • 8.10.1 Company Overview
    • 8.10.2 Financial Analysis
    • 8.10.3 Research & Development Expenses
    • 8.10.4 Recent strategies and developments:
      • 8.10.4.1 Partnerships, Collaborations, and Agreements:
      • 8.10.4.2 Trials and Approvals: